Tango Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company that discovers and develops precision medicines targeting cancer vulnerabilities, with a focus on mutant-selective and tumor-specific programs. The company offers a pipeline of novel small-molecule therapeutics, including TNG456 (first-in-class PRMT5-methyltransferase inhibitor for MTAP-deleted tumors), TNG348 (first-in-class MTA-cooperative PRMT5 inhibitor for solid tumors), TNG908 (brain penetrant LSD1 inhibitor for small cell lung cancer), and earlier-stage programs such as TNG462 (PRMT5 inhibitor for splicing factor mutant cancers) and discovery-stage assets targeting p53 and MRE11; these programs leverage the company's proprietary precision oncology platform combining bioinformatics, functional genomics, and chemistry to identify tumor cell dependencies. Tango Therapeutics operates primarily in the United States, with headquarters in Boston, Massachusetts, founded in 2019. Recent developments include the dosing of the first patient in the Phase 1/2 clinical trial of TNG348 in October 2024, positive initial data from the Phase 1/2 trial of TNG456 presented at ESMO 2024 showing clinical activity in MTAP-deleted pancreatic, NSCLC, and mesothelioma cancers, and the company's collaboration with Verastem Oncology to evaluate TNG456 in combination with avutometinib and defactinib in KRAS G12C mutant cancers announced in 2024.
Company News
Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey
Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX
Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE
ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX
Tango Therapeutics: Promising Early Data, But A Long Road Ahead
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics Announces Executive Chair Transition
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of “Moderate Buy” by Analysts
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.1% – Should You Buy?
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering